Recombinant Anti-PDL1 Antibody: High-Quality Solutions for Research Needs

Unlock the potential of immunotherapy with the Recombinant Anti-PDL1 antibody from Alpha Lifetech Incorporation. This cutting-edge antibody is designed to inhibit the pd-l1 pathway, a crucial mechanism that tumors exploit to evade immune detection. By blocking this pathway, the Recombinant Anti-PDL1 antibody enhances T-cell activation and promotes a robust anti-tumor response, making it an essential tool for cancer research and therapy development, With high specificity and affinity, this antibody is suitable for various applications, including ELISA, Western blotting, and flow cytometry, ensuring reliable results in your experiments. Alpha Lifetech Incorporation prides itself on delivering high-quality reagents, and our Recombinant Anti-PDL1 antibody is no exception. Every batch undergoes stringent quality control measures, providing researchers with confidence in their findings, Elevate your research on immune modulation and cancer biology with this innovative reagent, propelling your discoveries in cancer immunotherapy to new heights. Experience the Alpha Lifetech difference today!

Hot Selling Product

ADT1472-Opucolimab Biosimilar-(B7-H1/PD-L1/CD274)-Research Biosimilar Antibody

ADT1268-Garivulimab Biosimilar-(B7-H1/PD-L1/CD274)-Research Biosimilar Antibody

ADT1013-Adebrelimab Biosimilar (B7-H1/PD-L1/CD274)-Research Biosimilar Antibody

ALP64508-Recombinant Human Siglec-10 Protein, Fc Tag

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

Best Options For Recombinant Anti-PDL1 antibody Service Pioneers in the Field

In the rapidly evolving field of biotechnology, recombinant anti-PDL1 antibodies have emerged as a crucial tool for advancing immunotherapy and cancer research. At Alpha Lifetech Inc., we understand the importance of having access to high-quality reagents, which is why we pride ourselves on offering a robust selection of recombinant anti-PDL1 antibodies. Founded by a team of experienced scientists, our company focuses on membrane protein production, Nanobody discovery, and monoclonal development, ensuring that our clients receive the best options available. With nearly 10,000 high-quality spot membrane protein reagents, cytokines, and drug target antibodies in our catalog, Alpha Lifetech Inc. is committed to meeting the diverse needs of global buyers. Our recombinant anti-PDL1 antibodies are meticulously developed using rigorous standards, providing reliable and reproducible results for your research. As pioneers in the field, we strive not only to supply exceptional products but also to foster innovation and collaboration among scientists worldwide. Choosing Alpha Lifetech Inc. means partnering with a dedicated team that values quality, consistency, and scientific advancement. Whether you are involved in basic research or clinical applications, our comprehensive range of recombinant anti-PDL1 antibodies is designed to empower your projects and accelerate your findings. Discover how our solutions can elevate your work and contribute to groundbreaking discoveries in the fight against cancer.

Best Options For Recombinant Anti-PDL1 Antibody Service Pioneers in the Field

Service Provider	Recombinant Anti-PDL1 Antibody Type	Production Method	Purity Level	Delivery Time	Price Range
Provider A	Monoclonal	Recombinant	>95%	4-6 weeks	$500 - $800
Provider B	Polyclonal	Hybridoma	>90%	6-8 weeks	$400 - $700
Provider C	Recombinant Monoclonal	Phage Display	>98%	3-4 weeks	$600 - $900
Provider D	Recombinant	E. coli Expression	>95%	5-7 weeks	$550 - $850

Trends in Recombinant Anti-PDL1 Antibody Development Over Time

The development of recombinant anti-PDL1 antibodies has shown a significant increase over the past six years, as illustrated in the above chart. Starting from 10 new antibodies in 2018, the number has surged to an impressive 100 by 2023. This rapid growth reflects advancements in biotechnology and a rising interest in immune checkpoint inhibitors for cancer therapy. The trend highlights the scientific community's commitment to exploring potential therapeutics that can enhance the immune system's ability to fight tumors effectively. As shown in the graph, 2021 marked a notable leap in development, possibly influenced by extensive research funding and breakthroughs in related fields. The continuous rise in the number of developed antibodies indicates a robust pipeline that promises to yield innovative treatments for patients in the near future.